Jane Street Group LLC Takes Position in LivaNova PLC (LIVN)
Jane Street Group LLC bought a new position in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 8,720 shares of the company’s stock, valued at approximately $611,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LIVN. PNC Financial Services Group Inc. grew its position in shares of LivaNova by 9.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after buying an additional 153 shares during the last quarter. Riverhead Capital Management LLC grew its position in shares of LivaNova by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after buying an additional 763 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of LivaNova during the 2nd quarter valued at about $204,000. Bessemer Group Inc. bought a new stake in shares of LivaNova during the 2nd quarter valued at about $220,000. Finally, Martingale Asset Management L P bought a new stake in shares of LivaNova during the 2nd quarter valued at about $221,000. 86.07% of the stock is owned by institutional investors.
In other LivaNova news, Director Hugh M. Morrison sold 1,830 shares of the company’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total value of $161,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $74.58, for a total transaction of $74,580.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,830 shares of company stock valued at $488,550. 0.28% of the stock is owned by insiders.
LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, November 2nd. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.76 by $0.17. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The firm had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. During the same quarter in the prior year, the firm earned $0.78 EPS. LivaNova’s quarterly revenue was up 4.9% on a year-over-year basis. sell-side analysts forecast that LivaNova PLC will post 3.33 earnings per share for the current year.
A number of equities research analysts recently weighed in on the stock. Needham & Company LLC boosted their price objective on shares of LivaNova to $93.00 and gave the company a “buy” rating in a research report on Tuesday, November 21st. Canaccord Genuity reaffirmed a “hold” rating and set a $76.00 price objective on shares of LivaNova in a research report on Tuesday, December 5th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $85.00 price objective on shares of LivaNova in a research report on Friday, November 3rd. BidaskClub downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research raised shares of LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research report on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $79.71.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Stock Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related stocks with our FREE daily email newsletter.